GuatemalaTuberculosis profile
Population  2017 17 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.3 (0.29–0.32) 1.8 (1.7–1.9)
Mortality (HIV+TB only) 0.069 (0.05–0.091) 0.41 (0.29–0.54)
Incidence  (includes HIV+TB) 4.3 (3.3–5.4) 25 (19–32)
Incidence (HIV+TB only) 0.33 (0.25–0.41) 1.9 (1.5–2.4)
Incidence (MDR/RR-TB)** 0.13 (0.046–0.25) 0.75 (0.27–1.5)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.52 (0.29–0.75) 1.4 (0.78–2) 1.9 (1.2–2.6)
Males 0.49 (0.27–0.7) 1.9 (1.1–2.8) 2.4 (1.6–3.3)
Total 1 (0.69–1.3) 3.3 (2.3–4.3) 4.3 (3.3–5.4)
TB case notifications, 2017  
Total cases notified 3 505
Total new and relapse 3 445
          - % tested with rapid diagnostics at time of diagnosis 20%
          - % with known HIV status 94%
          - % pulmonary 94%
          - % bacteriologically confirmed among pulmonary 85%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 80% (63–100)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.09 (0.07–0.11)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 240 7%
          - on antiretroviral therapy 183 76%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  98
(39–160)
Estimated % of TB cases with MDR/RR-TB 2.3% (0.79–4.5) 13% (8.4–18)  
% notified tested for rifampicin resistance 28% 57% 1 036
MDR/RR-TB cases tested for resistance to second-line drugs   10
Laboratory-confirmed cases MDR/RR-TB: 75, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 62, XDR-TB: 1
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 87% 3 076
Previously treated cases, excluding relapse, registered in 2016 43% 54
HIV-positive TB cases registered in 2016 72% 170
MDR/RR-TB cases started on second-line treatment in 2015 51% 43
XDR-TB cases started on second-line treatment in 2015   0
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 28%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
62% (57–69)
TB financing, 2018  
National TB budget (US$ millions) 19
Funding source: 7% domestic, 9% international, 84% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2019-09-23 Data: www.who.int/tb/data